









Markets
/
Stocks
/
nasdaq-crbp
/

Corbus Pharmaceuticals Holdings Inc

CRBP

11.500USD

-0.120-1.03%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

140.92MMarket Cap

LossP/E TTM



Corbus Pharmaceuticals Holdings Inc

11.500

-0.120-1.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

31 / 506

Overall Ranking

115 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.667

Target Price

+249.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Undervalued

The company’s latest PE is -2.41, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 11.32M shares, decreasing 25.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 599.50K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.67

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.53

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.43, which is -28.83% below the recent high of -1.73 and 19.62% above the recent low of -1.96.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 31/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Corbus Pharmaceuticals Holdings Inc is 39.00, with a high of 55.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.667

Target Price

+253.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Corbus Pharmaceuticals Holdings Inc

CRBP

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.37, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 12.89 and the support level at 9.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.37

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.355

Buy

RSI(14)

69.836

Neutral

STOCH(KDJ)(9,3,3)

75.913

Buy

ATR(14)

0.671

High Vlolatility

CCI(14)

148.604

Buy

Williams %R

21.256

Buy

TRIX(12,20)

0.476

Sell

StochRSI(14)

91.507

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.876

Buy

MA10

10.246

Buy

MA20

10.069

Buy

MA50

9.415

Buy

MA100

8.591

Buy

MA200

9.039

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 92.35%, representing a quarter-over-quarter decrease of 2.77%. The largest institutional shareholder is The Vanguard, holding a total of 599.50K shares, representing 4.89% of shares outstanding, with 9.62% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

2.38M

OrbiMed Advisors, LLC

1.17M

Octagon Capital Advisors LP

1.11M

The Vanguard Group, Inc.

Star Investors

672.06K

+1.95%

Prosight Capital

575.14K

+113.01%

RA Capital Management, LP

430.18K

Paradigm BioCapital Advisors LP

399.66K

BlackRock Institutional Trust Company, N.A.

790.90K

-3.41%

Exome Asset Management LLC

289.69K

Comerica, Inc.

200.00K

+20000000.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.